Literature DB >> 30756015

Osteomalacia in a Case of Adult-Onset Bartter Syndrome.

Rashid Naseem Khan1,2, Farhana Saba1.   

Abstract

Bartter syndrome is a rare heterogeneous disease characterised by a deficiency in sodium and chloride absorption. Gain-of-function mutations in the CASR gene have been described in some patients with Bartter syndrome associated with hypocalcaemia and hypercalciuria. We describe a case of adult-onset Bartter syndrome with hypocalcaemia severe enough to cause osteomalacia. LEARNING POINTS: Bartter syndrome is one of the rare heterogenous diseases that present with electrolyte disturbances.Bartter syndrome type 5 also causes hypercalciuria which is not severe enough to cause osteomalacia.Patients with adult-onset Bartter syndrome should be screened promptly for osteomalacia to prevent pathological fractures and consequent complications.

Entities:  

Keywords:  Bartter syndrome; CaSR; hypocalcemia; hypokalemia; metabolic alkalosis; osteomalacia

Year:  2018        PMID: 30756015      PMCID: PMC6346954          DOI: 10.12890/2018_000764

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


INTRODUCTION

Bartter syndrome, first described by Bartter in 1962, comprises a set of autosomal recessive renal tubular disorders characterized by hypokalaemia, hypochloraemia, metabolic alkalosis and hyper-reninaemia with normal blood pressure[. Symptoms and severity vary between individuals but affected individuals generally have a mild form of the condition. It usually presents in young adulthood and is characterized by polyuria, fatigue, muscle cramps, spasms and tetany. Individuals may have low levels of parathyroid hormone, seizures and paraesthesias[. The calcium sensing receptor (CaSR) plays an important role in calcium homeostasis. Gain-of-function mutations in the CASR gene have been reported in some patients with Bartter syndrome associated with hypocalcaemia and hypercalciuria. Studies showed that these mutations result in receptor activation that is more severe than other gain-of-function mutations[. We describe a case of adult-onset Bartter syndrome with hypocalcaemia severe enough to cause osteomalacia.

CASE REPORT

A 28-year-old woman was admitted to Darul Sehat Hospital with a 3-month history of generalized weakness and fatigue and severe left hip pain for 2 days. The first episode of generalized physical aches, fatigue and left thigh pain had occurred 5 years previously when she was admitted to a different hospital and on laboratory work-up was found to have hypokalaemia. X-rays revealed a fracture of superior ramus of the left pubic bone and proximal parts of the right and left femurs (Figs. 1 and 2). She was conservatively managed for her fractures and her weakness improved with potassium replacement.
Figure 1

X-ray of the left femur and pelvis, February 2012

Figure 2

X-ray of the left femur and pelvis, September 2012

Thereafter she had been taking potassium supplements intermittently for her persistent hypokalaemia and calcium supplements but had never been thoroughly investigated. Now she had again developed the same but more severe symptoms. She denied taking laxatives and had no complaints of diarrhoea or vomiting. She had no significant family history and had normal dietary habits. On examination, the patient appeared relatively well. She was 147 cm tall and a weighed 50 kg. Her pulse rate was 98/min, blood pressure was 100/70 mmHg, and respiration rate was 16/min. Her left thigh was immobile and extremely tender, but there were no open wounds and no loss of sensation or vascular compromise. Examination of all other systems was unremarkable. Laboratory findings included serum sodium of 136 mEq/l, serum potassium of 2.6 mEq/l, serum chloride of 108 mEq/l, serum bicarbonate of 24 mEq/l, serum calcium of 9.2 mg/dl, serum phosphate of 1.94 mg/dl and alkaline phosphatase of 169 U/l. Blood urea nitrogen was 16 mg/dl, serum creatinine was 0.9 mg/dl and serum magnesium was 2.3 mg/dl. Electrocardiography showed T wave flattening. An x-ray of the left hip joint showed a fracture of the shaft of the left femur (Figs. 1–3). A DXA scan showed osteopaenia with a T-score of −1.9 (Tables 1 and 2, Figs. 4 and 5).
Figure 3

Fracture of the shaft of the left femur, April 2016

Table 1

DXA results for the lumbar spine

RegionArea (cm2)BMC (g)BMD (g/cm2)T-scoreZ-scoreAM (%)
L111.6117.661.5205.45.6168
L211.5619.841.7166.36.5171
L312.5822.251.7696.26.5167
L414.6724.261.6675.05.2153
Total50.4384.211.6705.75.9163

AM, age matched; BMC, bone mineral content; BMD, bone mineral density.

Table 2

DXA results summary

RegionArea (cm2)BMC (g)BMD (g/cm2)T-scoreZ-scoreAM (%)
Neck3.632.220.610−2.2−1.975
Troch7.505.150.686−0.2−0.199
Inter16.1813.580.839−1.7−1.677
Total27.3120.950.767−1.4−1.383
Ward’s0.950.490.512−1.9−1.377

AM, age matched; BMC, bone mineral content; BMD, bone mineral density.

Figure 4

DXA scan, March 2016

Figure 5

DXA scan, March 2016

Serum vitamin D was 31 ng/ml (deficiency: <20 ng/ml). Serum PTH was 182.0 pg/ml (normal: 7–53 pg/ml), plasma renin was 148.0 μIU/ml (normal: 4.4–46.1 μIU/ml erect) and serum aldosterone was 20 ng/dl (normal: <15 ng/ml). The 24-hour urinary excretion of sodium was 182 mEq, potassium 68 mEq, chloride 240 mEq, calcium 120 mg, protein 150 mg and glucose 30 mg, and urine amount was 2,200 ml. The urinary specific gravity was 1.010 and osmolality was 320 mOsm/kg. The patient’s previous laboratory findings when she first started having generalized physical aches and hypokalaemic episodes were serum calcium of 7.62 mg/dl, serum phosphate of 2.48 mg/dl, alkaline phosphatase of 166 U/l and serum potassium of 2.7 mEq/l. The patient was treated with potassium chloride, calcium and vitamin D supplements. Her serum potassium concentration improved from 2.6 mEq/l to 3.1 mEq/l, her muscle strength rapidly recovered and she did well. Her femur fracture was conservatively managed and also began to heal.

DISCUSSION

More than 230 different germline mutations of the CaSR, which is encoded by the CASR gene located on chromosome 3q21.1, have been reported. These mutations may cause severe loss of CaSR function associated with hypocalcaemic disorders such as Bartter syndrome type 5, which is characterised by renal salt wasting, hypokalaemic alkalosis and hyper-reninaemic hyperaldosteronism[. Four genes have been identified which can cause Bartter syndrome: SLC12A2, encoding the sodium-potassium-chloride cotransporter NKCC2; KCNJ1, encoding the ROMK1 potassium ion channel; CLCNKB, encoding the ClC-Kb basolateral chloride ion channel; and BSND, encoding barttin, a regulatory subunit required for basolateral chloride channel targeting to the membrane. Bartter type 5 is distinguished from the other types by its autosomal dominant transmission and the presence of hypocalcaemic hypercalciuria[. Several studies have described the pathophysiology of this syndrome (Tables 3 and 4). A few cases have been reported, but Bartter syndrome with hypocalcaemia severe enough to cause osteomalacia has not previously been reported.
Table 3

Pathophysiology

AuthorYearDefect
Gardner et al. [6]1970Primary defect in membrane transport, based on studies of sodium content and outflux of erythrocytes
Ramos et al. [7]1980Defect in chloride reabsorption in the ascending thick limb of Henle’s loop, leading to hypokalaemia
Baehler et al. [8]1980Primary defect in the reabsorption of sodium chloride in the ascending limb and not renal potassium wasting
Table 4

Case reports

AuthorYearCase report
Vezzoli et al. [9]2006Case of twin sisters with autosomal dominant hypocalcaemia due to a K29E activating mutation of the CASR gene and Bartter syndrome. They had a mild phenotype
Choi et al. [10]2015Patient with autosomal dominant hypocalcaemia with Bartter syndrome

CONCLUSION

In this case, the patient was diagnosed with adult-onset Bartter syndrome because of hypokalaemia, relative hypotension, increased renin activity and increased aldosterone level. Following treatment, serum potassium concentration improved and the patient’s muscle strength rapidly recovered. The osteomalacia caused by the disease and found at the same time was also treated and the patient was doing well by her next follow-up visit.
  7 in total

1.  Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome.

Authors:  F C BARTTER; P PRONOVE; J R GILL; R C MACCARDLE
Journal:  Am J Med       Date:  1962-12       Impact factor: 4.965

2.  Autosomal dominant hypocalcemia with mild type 5 Bartter syndrome.

Authors:  Giuseppe Vezzoli; Teresa Arcidiacono; Vera Paloschi; Annalisa Terranegra; Rita Biasion; Giovanna Weber; Stefano Mora; Marie Louise Syren; Domenico Coviello; Daniele Cusi; Giuseppe Bianchi; Laura Soldati
Journal:  J Nephrol       Date:  2006 Jul-Aug       Impact factor: 3.902

3.  Studies on the pathogenesis of Bartter's syndrome.

Authors:  R W Baehler; J Work; T A Kotchen; G McMorrow; G Guthrie
Journal:  Am J Med       Date:  1980-12       Impact factor: 4.965

4.  Surreptitious habitual vomiting simulating Bartter's syndrome.

Authors:  E Ramos; M Hall-Craggs; L M Demers
Journal:  JAMA       Date:  1980-03-14       Impact factor: 56.272

5.  Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome.

Authors:  Rosa Vargas-Poussou; Chunfa Huang; Philippe Hulin; Pascal Houillier; Xavier Jeunemaître; Michel Paillard; Gabrielle Planelles; Michèle Déchaux; R Tyler Miller; Corinne Antignac
Journal:  J Am Soc Nephrol       Date:  2002-09       Impact factor: 10.121

6.  Autosomal dominant hypocalcemia with Bartter syndrome due to a novel activating mutation of calcium sensing receptor, Y829C.

Authors:  Keun Hee Choi; Choong Ho Shin; Sei Won Yang; Hae Il Cheong
Journal:  Korean J Pediatr       Date:  2015-04-22

Review 7.  Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis.

Authors:  Fadil M Hannan; Valerie N Babinsky; Rajesh V Thakker
Journal:  J Mol Endocrinol       Date:  2016-10       Impact factor: 5.098

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.